Britt Stroud
Neurology with Special Qualifications in Child Neurology · Port Charlotte, FLNPI 1336368927
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,900 of the $10,726 with a category attached, or 64.3%. Novartis accounts for 75.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $8,748, 7.8 times the $1,116 reported in 2019.
Across 91 payments — averaging $117.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- Livanova USA, Inc.$325
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$305
- Sunovion Pharmaceuticals Inc.$275
- UCB, Inc.$230
- Eisai Inc.$145
- plus $1K from 24 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$2K
What the payments were for
- Consulting fees$6,90064%
- Travel & lodging$9639%
- Food & beverage$2,85527%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $8,117 |
| Livanova USA, Inc. | 5 | $325 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 4 | $305 |
| Sunovion Pharmaceuticals Inc. | 18 | $275 |
| UCB, Inc. | 8 | $230 |
| Eisai Inc. | 2 | $145 |
| Genentech USA, Inc. | 2 | $138 |
| Tris Pharma Inc | 6 | $124 |
| Sumitomo Pharma America, Inc. | 1 | $123 |
| Genentech, Inc. | 1 | $114 |
| Corium, LLC | 4 | $90 |
| Jazz Pharmaceuticals Inc. | 4 | $87 |
| Otter Pharmaceuticals, LLC | 3 | $86 |
| Neurelis, Inc. | 1 | $85 |
| Catalyst Pharmaceuticals, Inc. | 2 | $67 |
| Ironshore Pharmaceuticals Inc. | 3 | $60 |
| Aucta Pharmaceuticals, Inc. | 3 | $54 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| AbbVie | 2 | $26 |
| Nobelpharma America, LLC | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Sarepta Therapeutics, Inc. | 1 | $23 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| Zogenix Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Saol Therapeutics Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVRYSDI$237
- ZOLGENSMA$209
- VNS Therapy$147
- Fycompa$124
- APTIOM$123
How this compares
$10,726 in reported general payments places this provider in the 70th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamictal XrLamotrigine | 30 | $68,739 |
| Trokendi XrTopiramate | 12 | $46,148 |
| Lamictal OdtLamotrigine | 16 | $21,407 |
| Levetiracetam | 20 | $841 |
| Baclofen | 15 | $399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $50 | $46,14812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
Other neurology with special qualifications in child neurology in Port Charlotte
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Natalie GillsonFort Myers$250K
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ronald DavisWinter Park$154K
- Ian MillerMiami$104K
- Michael HammerSaint Petersburg$100K
- Matt LallasMiami$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.